8^th Molecular Immunology & Immunogenetics Congress March 20-21, 2017 Rome, Italy

Professor Giulio Tarro graduated from Medicine School, Naples University (1962). Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. Oncological Virology Professor, Naples University (1972-1985). Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus, 2006. Since 2007 Chairman Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010). President Foundation de Beaumont Bonelli for Cancer Research.

Murine Virology, Antiviral Chemotherapy, Immunology, Effects of inhibitors on viral replication, Studies on the role of herpesviruses in cancer, Tumor immunology, Pathology of AIDS.

Dr. Michael G Hanna, Jr. received his PhD in experimental pathology and immunology from the University of Tennessee (TN, USA) in the 1960s. He was a consultant with NASA for the lunar receiving laboratory during Apollo 11 and 12, for which his expertise in immunology was used in the testing of the lunar core powder for immunogenic or pathogenic materials. Dr. Hanna served during 1974–83 as Director of the National Cancer Institute, Frederick Cancer Research Center (MD, USA).

He was Chief Operating Officer during 1985–94 of Organon Teknika/Biotechnology Research Institute and Senior Vice President of Organon Teknika Corporation, a subsidiary of Akzo Nobel, Netherlands. He developed and obtained approvals for TICE BCG for the treatment of carcinoma in situ (CIS) bladder cancer, which remains the standard of care for prophylaxis of recurrence of superficial bladder cancer and therapy of CIS. Subsequently, Dr. Hanna founded PerImmune Inc., for which he served as President and Chief Executive Officer before it merged with Intracel Corp. in 1998. He continued to work for Intracel Resources as Chief Scientific Officer and Chairman.

In 2007, Dr. Hanna founded Vaccinogen Inc., where he served as Chairman and CEO. Currently, Dr. Hanna is Chairman Emeritus. The company is a pioneer in the field of cancer vaccines and is developing OncoVAX, an autologous vaccine designed to elicit a specific immune response against cancer cells. The Phase 3 vaccine is being investigated for treatment mainly of colon cancer, but also for melanoma and renal cell carcinoma.

In addition to cancer therapy research and development, Dr. Hanna has been involved in Homeland Security. He served as Chairman of the Department of Commerce Biotechnology Advisory Committee (1984–9) and also participated in the Department of Defense Technical Working Group for Biotechnology (1988–9). PerImmune completed a Department of Defense contract to manufacture the current effective therapeutic for Botulinum toxin, an equine heptavalent anti-toxin. Dr Hanna’s research resulted in over 225 publications in international peer-reviewed journals and book chapters, and he holds 10 patents related to immunotherapy. Dr Hanna has been the recipient of numerous honors and awards and has served on many editorial boards, including for Human Vaccines & Immunotherapeutics.

Cancer Vaccines, Active Specific Immunotherapy, Humoral Immunity, Tumor Antigens.

Yaffa Mizrachi Nebenzahl has completed her PhD at The Weizmann Institute, Israel in 1985. She is the Head of the Molecular Microbiology Laboratory in The Shraga Segal Department of Microbiology, Immunology and Genetics at the Faculty of Health Sciences in Ben Gurion University of the Negev, Israel.

Immunology, molecular biology, infectious diseases, bio chemistry, pneumonia, innate Immunity.

Dr. Jessy Deshane is currently an Associate Professor of Medicine at UAB. Since starting her own laboratory in January 2011, she focused her laboratory research program on immune regulation by myeloid-derived regulatory cells (MDRCs) in chronic inflammatory lung diseases. Dr. Jessy team have recently identified and characterized these free radical producing myeloid-lineage cells as master regulators of allergic airway inflammation. Her laboratory is particularly interested in delineating mechanisms underlying the differentiation and function of MDRCs in the establishment and resolution of inflammation. They are currently investigating the novel hypothesis that MDRCs can produce neo-antigens that trigger dysregulated immune responses in asthma. The impact of environmental exposures on MDRCs and generation of neo-antigens is also of great interest to her lab. She has recently extended her program to investigate novel strategies to target immunosuppression by myeloid-lineage cells and to reprogram the metabolism in the tumor microenvironment. Her team anticipates that their strategies will enhance persistent memory response for lung cancer.

Immune regulation, Asthma, Molecular Immunology, Tumor, Cancer

Dr. Rao is a professor of Microbiology, Parasitology, Immunology , Pharmacology and Epidemiology in many universities, many medical colleges in India, China, Nepal, Libya, and Philippines. Currently he is working as professor of Microbiology, Parasitology, Immunology and Dean of Student Affairs at Avalon University School of Medicine, Curacao, Netherland Antilles. Dr. Rao has more than 44 years of teaching and research experience. Supervised 4 students for Ph.D,. Authored 18 text books. 3 Universities appointed as their adviser . Presented 18 full length papers exclusively during 2015 to 2016 in different international journals. Accepted as organizing committee member for 3 international conferences in 2016. Invited Key note speaker and speaker for many conferences, universities and colleges. The Royal Society United kingdom awarded me three fellowships in 2016 for my current advanced research in Medicine. Dr Rao is post doctoral supervisor too. Dr Rao,is Editor -in chief and Editor for more than 12 international journals.

Parasitic infections are more in tropical countries and cause global health problem especially in developing countries, Advanced diagnostics, tests, vaccines, therapeutics and development of new drugs are needed. Viviparity is common among est mammals but not many provide long gestation period, To study long term parasitic toxic effects, it is essential to use long gestation period laboratory animal models. Rats have 21 days, rabbits 30,dog 60 days of gestation period, The subtle effects of Thalidomide tragedy resulting in phocomalia, apoda etc in the offspring lead to untold miseries, Similarly good number of cases of fetal deaths, still births, teratogenices etc. Dr.Rao used scorpion as model in estimation of heavy metals like mercury and lead in embryonic development of scorpion and noticed similar effects, Indeed great challenges, given that most drugs in pipe line failed in clinical trails. Because most of the drugs tested on low gestation period animals, A new thought in the drug design for parasitic diseases by using scorpion as a model. Introducing parasite in scorpion and observing the drug effects and reversal effects, In addition to clinical work, developed a variety of basic and transnational research programs, participated to Ph.D. programs.

Eugenio Luigi Iorio is an eclectic medical doctor with many different field of interest, he did doctorate in Biochemical Sciences. He is the president of International Observatory of Oxidative Stress (Salerno, Italy). According to his research, the identification and the control of oxidative stress, an emerging health risk factor related to the dysregulation of redox systems, may play a relevant role in the prevention and treatment of life-style related disorders. After 15 years of research he funded in 2007 the International Observatory of Oxidative Stress (IOOS), a no-profit scientific network of more than 3,000 researchers living in 35 different Countries, which main goal is to translate into the clinical practice the basic knowledge on free radicals and antioxidants as the ancient modulating mechanism of all living functions. As the President of IOOS Iorio promotes and realises worldwide programs aimed to improve or to maintain the quality of life through personalised interventions on life-style, by using the redoxomics approach that allows to measure the level of oxidative stress even in real time.

Oxidative Stress, Biochemistry

Ishak Ozel Tekin received the Doctor of Medicine in 1993 from Gazi University Ankara, Turkey. He received the PhD degree in Immunology in Gazi University in 1999. In 2000, he moved to Zonguldak Karaelmas University where he founded the second department of immunology in Turkey the same year. He is the Head of Department of Immunology in Bulent Ecevit University, School of Medicine. He is mainly interested in inflammation and oxidative stress. He is a member of Turkish Immunology Society, Turkish Thorax Society, Turkish Association of Wound Care and Repair, European Respiratory Society, World Society of Interdiciplinary Anti-Aging Medicine. He is the scientific director of Immune-Aging Division of Regenera Research Group.

Immunology, Inflammation, Oxidative Stress

Dr. Fenniri was educated at the University of Louis Pasteur in Strasbourg, France and received his undergraduate degree in chemistry and biochemistry (1989, top of his class) and his M.Sc. /Ph.D. degrees in supramolecular science and engineering (1990/1994) under the supervision of Professor Jean-Marie Lehn (Nobel Laureate). He then joined the Scripps Research Institute in California, USA, where he carried out his postdoctoral training under the supervision of Professor Richard A. Lerner (President and CEO). In 1997 he moved to Purdue University, where he initiated his independent academic career, and established the Purdue Laboratory for Chemical Nanotechnology (1999). In 2003, He joined the National Research Council and the University of Alberta to build and lead the Supramolecular Nanoscale Assembly program, and contribute to the shaping of the National Institute for Nanotechnology (NINT), its research programs and facilities, and the recruitment of highly qualified personnel. NINT has since grown from 4 principal investigators in 2003 to a vibrant research and technology organization of over 350 researchers in 2013.

In addition Dr. Fenniri held a full professor position with the Department of Chemistry (since 2003-2013) and adjunct full professor positions with the department of biomedical engineering (since 2010) with the faculty of medicine and with the department if Chemistry (since 2013) at the University of Alberta. Dr. Fenniri is currently Professor Chemical and Biomedical Engineering at Northeastern University, Boston, MA, USA.

Dr. Fenniri has achieved international recognition as a leader in the areas of self-assembly, supramolecular chemistry, nanomedicine, combinatorial chemistry, and materials sciences. His group works at the forefront of basic and applied nanosciences, in collaboration with various academic institutions, federal laboratories, and with the private sector. Dr. Fenniri’s contributions appeared in over 190 publications, 8 patents, and over 400 contributed national and international conference papers. Dr. Fenniri has also presented his work in over 150 invited distinguished lectures, colloquia and seminars around the globe. His research programs are supported by the Natural Science and Engineering Research Council of Canada, Alberta Advanced Education and Technology, the US National Institutes of Health, the National Research Council of Canada, the University of Alberta, and several private, provincial and federal funding organizations.

Dr. Fenniri is the recipient of several academic and professional honours and awards, including the Xerox UAC Award (2006–2008), the 3M Faculty Award (2000, 2002), the Showalter Trust Fund Award (1999, 2001), the Trask Trust Fund Technology Innovation Award (2000), the Cottrell Teacher Scholar Award (2000–2005), and the US National Science Foundation Career Award (1999–2003). Dr. Fenniri is Member of the Editorial Board of several scientific journals and serves on several national and international scientific boards, panels, and committees.

Nanotechnology for biomedical applications, Nanoscale materials for drug delivery, Cell therapeutics and regenerative medicine.

For more than 10 years is working actively to endocrine and metabolic diseases in prostate cancer at the Department of Medicine and Science of Aging of University G. d\'Annunzio of Chieti-Pescara, Italy. In particular, recently her research work has been awarded by the Italian Society of Urology, analyzing the complex relationship between changes in bone metabolism, renal function and immune structure in prostate cancer. She is currently a professor at the Postgraduate School of Urology at the University G. D'Annunzio of Chieti-Pescara. She also founded in 2015 at the People's University Nicholas Copernicus the Department of Urologic Sciences, Biomedical and Translational, of which She is a Director.

Simona Di Francesco research interest is in Urological Cancer and Immunology, Prostate and Immunology, Bladder and Immunology, Kidney and Immunology.

Noah Isakov is a Professor of Immunology and Chair of The Shraga Segal Department of Microbiology and Immunology at the Faculty of Health Sciences Ben Gurion University of the Negev Beer Sheva Israel. He received his PhD from the Weizmann Institute of Science in Rehovot Israel 1981 and performed postdoctoral studies at the University of Minnesota in Minneapolis MN 1981-1983 and the Scripps Research Institute in La Jolla CA 1983-1987. He performed a Sabbatical at the National Institute of Allergy and Infectious Diseases at the NIH Bethesda MD 1993-1995 and served as an Esther Z Greenberg Honors Chair in Biomedical Research at the Oklahoma Medical Research Foundation in Oklahoma City OK 2003-2004 and President of the Israel Immunological Society 2004-2006.

Immunology, signal transduction, biochemistry, cellular and molecular biology.

Burak Karacaören received his B.Sc. degree in Animal Science (Faculty of Agriculture) and M.Sc. in Biometry and Genetics (Institute of Natural Sciences) from Akdeniz University, Antalya, Turkey in 1999 and 2001 respectively. He spent 6 months in As, Agricultural University of Norway, Norway about animal production and statistics. He received his Dr.Sc.degree in Statistical Animal Genetics Group (Institute of Animal Sciences) from Swiss Federal Institute of Technology Zurich (ETH Zurich), Switzerland at 2006. As a part of his doctorate studies he spent 2 months in INRA Paris, France. He was a post doctoral researcher at the Roslin Institute, University of Edinburgh, Scotland, UK in Genetics and Genomics department and at the Laurentian Forestry Institute, University of Laval, Quebec, Canada in forestry genomics in 2008-2010 and 2010-2011 respectively. Currently he is an assistant professor in Biometry and Genetics Section, Department of Animal Science at Akdeniz University, Turkey.

Burak Karacaoren main research interests are in statistical methods applied to genetics, genomics and animal breeding.